Luye Pharma : LY03005 Approved by China's CDE to Conduct Phase III Clinical Trial for the Treatment of Generalized Anxiety Disorder - Marketscreener.com

Submitted by Anonymous (not verified) on Mon, 03/21/2022 - 22:59

Luye Pharma : LY03005 Approved by China's CDE to Conduct Phase III Clinical Trial for the Treatment of Generalized Anxiety Disorder  Marketscreener.com